Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · IEX Real-Time Price · USD

143.31

-0.40 (-0.28%)

At close: Apr 26, 2024, 4:00 PM

146.13

+2.82 (1.97%)

After-hours: Apr 26, 2024, 5:12 PM EDT

Alnylam Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2003
Cash & Equivalents	812.69	866.39	819.98	496.58	547.18	420.15	645.36	193.62	180.9	75.18	Upgrade
Short-Term Investments	1,627	1,326	1,616	1,378	988.98	664.01	1,045	433.18	899.64	621.51	Upgrade
Cash & Cash Equivalents	2,439	2,192	2,436	1,874	1,536	1,084	1,691	626.8	1,081	696.69	Upgrade
Cash Growth	11.27%	-9.98%	29.94%	22.02%	41.69%	-35.87%	169.72%	-41.99%	55.09%	183.36%	Upgrade
Receivables	327.79	237.96	198.57	102.41	43.01	18.76	34	23.33	8.3	39.94	Upgrade
Inventory	89.15	128.96	86.36	75.2	56.35	24.07	0	0	0	0	Upgrade
Other Current Assets	126.38	132.92	88.08	562.77	80.34	73.71	40.12	21.74	16.56	9.74	Upgrade
Total Current Assets	2,983	2,692	2,809	2,615	1,716	1,201	1,765	671.88	1,105	746.37	Upgrade
Property, Plant & Equipment	725.79	738.63	733.63	706.51	646.38	320.66	181.9	114.57	27.81	21.74	Upgrade
Long-Term Investments	49.39	49.39	40.89	40.73	14.83	44.83	43.92	474.8	251.84	279.82	Upgrade
Other Long-Term Assets	72	66.09	60.2	45.05	18.07	8.62	4.17	1.56	1.47	31.67	Upgrade
Total Long-Term Assets	847.18	854.11	834.73	792.28	679.27	374.11	229.99	590.93	281.12	333.23	Upgrade
Total Assets	3,830	3,546	3,643	3,407	2,395	1,575	1,995	1,263	1,387	1,080	Upgrade
Accounts Payable	55.52	98.09	73.43	51.97	49.88	59.71	28.36	54.47	16.79	15.11	Upgrade
Deferred Revenue	290.93	235.9	301.84	352.3	396.2	3.95	84.78	82.93	68.32	66.85	Upgrade
Current Debt	41.51	41.97	40.55	36.87	27.69	0	0	0	0	0	Upgrade
Other Current Liabilities	579.83	391.96	279.89	144.13	-121.18	115.83	31.12	-5.7	-23.01	13.37	Upgrade
Total Current Liabilities	967.79	767.92	695.71	585.27	352.59	179.49	144.25	131.7	62.1	95.33	Upgrade
Long-Term Debt	1,264	1,278	957.04	484.32	276.14	30	30	150	0	0	Upgrade
Other Long-Term Liabilities	1,819	1,658	1,402	1,321	327.71	63.34	54.05	60.89	59.7	47.99	Upgrade
Total Long-Term Liabilities	3,083	2,937	2,359	1,806	603.85	93.34	84.05	210.89	59.7	47.99	Upgrade
Total Liabilities	4,051	3,705	3,055	2,391	956.44	272.84	228.3	342.59	121.8	143.33	Upgrade
Total Debt	1,305	1,320	997.59	521.19	303.82	30	30	150	0	0	Upgrade
Debt Growth	-1.13%	32.34%	91.41%	71.54%	912.74%	-	-80.00%	-	-	-	Upgrade
Retained Earnings	-7,009.59	-6,569.35	-5,438.19	-4,585.37	-3,727.09	-2,840.97	-2,147.69	-1,656.81	-1,246.7	-956.63	Upgrade
Comprehensive Income	-23.38	-44.65	-33.26	-43.62	-36.52	-33.21	-34.43	-33.44	4.37	48.76	Upgrade
Shareholders' Equity	-220.64	-158.22	588.2	1,016	1,439	1,302	1,766	920.22	1,265	936.27	Upgrade
Net Cash / Debt	1,134	872.16	1,438	1,353	1,232	1,054	1,661	476.8	1,081	696.69	Upgrade
Net Cash / Debt Growth	30.02%	-39.35%	6.26%	9.81%	16.90%	-36.52%	248.28%	-55.87%	55.09%	183.36%	Upgrade
Net Cash Per Share	9.08	7.17	12.14	11.77	11.28	10.48	18.34	5.57	12.86	9.38	Upgrade
Working Capital	2,015	1,924	2,113	2,030	1,363	1,021	1,620	540.18	1,043	651.03	Upgrade
Book Value Per Share	-1.77	-1.30	4.97	8.84	13.17	12.94	19.51	10.75	15.06	12.61	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).